Niagen Bioscience, Inc.
NAGE
$3.65
-$0.15-3.95%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 32.13% | 103.30% | 1,275.69% | 1,411.32% | 499.80% |
| Total Depreciation and Amortization | -39.78% | -47.10% | 44.79% | 16.72% | -1.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 143.15% | 443.06% | -120.74% | -139.24% | -143.19% |
| Change in Net Operating Assets | -349.24% | -364.71% | 116.75% | 204.64% | 406.51% |
| Cash from Operations | -77.52% | 11.52% | 412.77% | 1,871.28% | 326.34% |
| Capital Expenditure | -108.44% | -79.14% | -126.09% | -177.00% | -57.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | 300.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 3,820.15% | -104.20% | -173.68% | -157.00% | -44.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 18.18% | -9.09% | -20.00% | -33.33% | 35.29% |
| Issuance of Common Stock | -50.35% | 33.39% | 558.68% | 1,856.52% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -129.79% | -28.85% | 38.37% | 38.37% | 45.35% |
| Cash from Financing | -82.08% | 28.81% | 595.40% | 2,213.12% | 8,340.78% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.02% | 16.11% | 466.97% | 2,103.45% | 534.06% |